Pay in 4 interest-free payments of $5.51 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
From topical research: Most commonly reported observation: mild transient redness at application site (attributed to vascular activity from VEGF stimulation) No systemic adverse events reported in human topical studies at standard concentrations No evidence of carcinogenicity or mutagenicity in available in vitro models From injectable research (preclinical): At supratherapeutic doses in animal models, mild injection site reactions have been noted No organ toxicity observed in standard preclinical safety panels No immunogenicity concerns identified (consistent with its endogenous structure) Copper considerations: GHK-Cu delivers a small amount of bioavailable copper
Mechanism in research How BPC-157 + TB-500 Blend is studied In published research BPC-157 was associated with accelerated tissue healing across animal injury models, while Thymosin Beta-4 (the parent of TB-500) was reported to support cell migration, angiogenesis, and tissue repair
not for human or veterinary application References Brines M., Cerami A
Hata S, Saito H, Kakiuchi T, et al (2023) Brain p3Alc peptide restores neuronal viability impaired by Alzheimers amyloid peptide
